Genzyme, Duke University, University of California deal

GENZ and the universities will develop molecular therapies to treat cardiovascular diseases. The company will provide vectors

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE